Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis

Current drug development efforts on gastric cancer are directed against several molecular targets driving the growth of this neoplasm. Intra-tumoral biomarker heterogeneity however, commonly observed in gastric cancer, could lead to biased selection of patients. MET, ATM, FGFR2, and HER2 were profil...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2015-11, Vol.10 (11), p.e0143207-e0143207
Hauptverfasser:	Ye, Peng, Zhang, Meizhuo, Fan, Shuqiong, Zhang, Tianwei, Fu, Haihua, Su, Xinying, Gavine, Paul R, Liu, Qiang, Yin, Xiaolu
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Angiogenesis Ataxia Ataxia Telangiectasia Mutated Proteins - genetics Biomarkers Biomarkers, Tumor - genetics Biopsy Breast cancer Cancer Cancer therapies Cell cycle Clinical trials Deoxyribonucleic acid DNA Drug development ErbB-2 protein False Negative Reactions Fibroblast growth factor receptor 2 Gastric cancer Gene Amplification Gene Expression Profiling Gene Expression Regulation, Neoplastic Growth factors Health care Heterogeneity Hospitals Humans Immunohistochemistry In Situ Hybridization, Fluorescence Kinases Medical innovations Medical prognosis Metastasis Neoplasia Ovarian cancer Patients Precision Medicine - methods Proteins Proto-Oncogene Proteins c-met - genetics R&D Receptor, ErbB-2 - genetics Receptor, Fibroblast Growth Factor, Type 2 - genetics Research & development Risk Assessment Statistical analysis Statistical methods Statistics Stomach cancer Stomach Neoplasms - genetics Stomach Neoplasms - pathology Stomach Neoplasms - therapy Tumorigenesis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!